Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

This review examines its erectile dysfunction (ED) services, looking closely at what Hims offers its users, comparing its prices, researching how long it takes for Hims ED medications to work ...

Telehealth company Hims & Hers Health (HIMS ... it will stop offering compounded semaglutide on its platform after the first quarter, triggering mixed reviews from analysts about the future ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Hims & Hers turned in tremendous revenue and profitability growth in the fourth quarter. The company also issued very robust guidance. However, it will stop selling semaglutide-based weight-loss ...

24/7 Wall St. Insights: Hims & Hers Health continues to get crushed by the shortage of semaglutide getting resolved, which jeopardizes the direct-to-consumer healthcare platform’s growth trajectory.

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ... But some recent Hims and Hers reviews complain about ...

Even as Hims phases out mass-compounded semaglutide—the active ingredient in Wegovy—it still projects rapid weight-loss growth. Its outlook for 2025 includes some $725 million in weight-loss ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Additionally, the FDA last week hindered the ability of compounded drugmakers, including HIMS, to sell lower-cost versions of semaglutide, the weight-loss drug that has proliferated widely. The news ...